TKToshiya Katsura

Toshiya Katsura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Toshiya Katsura has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Satoshi Ueshima

    College of Pharmaceutical Sciences, Ritsumeikan University, Kusatsu, Japan

    5 shared publications
  • Yohei Tabuchi

    Department of Pharmacy, Shiga University of Medical Science Hospital, Otsu, Japan

    4 shared publications
  • Chiho Tomitsuka

    College of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Noji-Higashi, Kusatsu, Shiga, 525-8577, Japan

    3 shared publications
  • Hideki Itoh

    Department of Cardiovascular Medicine, Shiga University of Medical Science, Seta Tsukinowa-Cho, Otsu, Japan

    3 shared publications
  • Minoru Horie

    Department of Cardiovascular Medicine, Shiga University of Medical Science, Seta Tsukinowa-Cho, Otsu, Japan

    3 shared publications
  • Tomohiro Terada

    Department of Pharmacy, Shiga University of Medical Science Hospital, Otsu, Japan

    3 shared publications

Latest Publications

  • Open Access

    Population pharmacokinetics and pharmacogenomics of edoxaban in Japanese adults with atrial fibrillation

    by Satoshi Ueshima, Daiki Hira, Sayana Matsuda, Rio Michihata, Yohei Tabuchi, Tomoya Ozawa, Hideki Itoh, Moritake Iguchi, Masaharu Akao, Takanori Aizawa, et al.

    Background: Edoxaban is used as an anti-coagulant to prevent cardioembolic infarction, deep vein thrombosis, and pulmonary embolism. Edoxaban pharmacokinetics have been reported to be affected by several factors such as renal function, age, body weight, and the concomitant use of P-glycoprotein inhibitors. However, the relationship between genetic polymorphisms in drug metabolizing enzymes and transporters and the inter-individual variability of edoxaban pharmacokinetics in patients with atrial fibrillation (AF) remains unclear. Additionally, there is little information concerning PPK analysis using real world data. In this study a population pharmacokinetic and pharmacogenomic analysis was conducted to clarify covariate factors affecting the edoxaban pharmacokinetics in Japanese adult AF patients. Methods: One hundred and thirty-one blood samples were collected from 131 patients. The edoxaban pharmacokinetic profile was described by a one-compartment model, and pharmacogenomic data were stratified according to CYP3A5 (CYP3A5*3) and ABCB1 (ABCB1 1236 C > T, 2677G > T/A, and 3435 C > T) polymorphisms. A non-linear mixed-effects modeling software (NONMEM™) was used to evaluate the effects of patient characteristics and genetic polymorphisms on the edoxaban pharmacokinetics. Results: The apparent oral clearance (CL/F) of edoxaban was estimated, and the apparent volume of distribution was fixed at the reported value. The CL/F of edoxaban was correlated non-linearly with creatinine clearance (CLcr), wherein the population mean CL/F for a typical patient (CLcr = 61.8 mL/min) was estimated to be 28.2 L/h. Other clinical laboratory data and genetic polymorphisms, excluding CLcr, did not affect the edoxaban pharmacokinetics. Conclusions: These results suggest that genetic polymorphisms of CYP3A5 and ABCB1 are not considered intrinsic factors affecting edoxaban pharmacokinetics in Japanese adult AF patients. Similarly to previous studies, renal function affects its pharmacokinetics. These findings may provide useful information for individualized anticoagulant therapy with edoxaban to prevent adverse events without reference to genetic polymorphisms of CYP3A5 and ABCB1.


  • Attenuation of phenobarbital‐induced cytochrome P450 expression in carbon tetrachloride‐induced hepatitis in mice models

    by Chieri Fujino, Taiki Kuzu, Yukine Kubo, Kurumi Hayashi, Satoshi Ueshima, Toshiya Katsura

    Certain pathological conditions, such as inflammation, are known to affect basal cytochrome P450 (CYP) expression by modulating transcriptional regulation, and the pharmacokinetics of drugs can vary among patients. However, changes in drug‐induced CYP expression under pathological conditions have not been elucidated in detail. Here, we investigated the effects of hepatic inflammation and injury on phenobarbital‐induced expression of CYP isoforms in mice. Phenobarbital was administered once as a CYP inducer in the carbon tetrachloride‐induced hepatitis model mice. The mRNA expression levels of Cyp3a11 and Cyp2b10 in the liver and small intestine were measured using reverse transcription polymerase chain reaction. The enzymatic activity of CYP3A in liver S9 was evaluated using midazolam as the substrate. Phenobarbital increased the mRNA expression of Cyp3a11 and Cyp2b10 in the liver of healthy mice, but not in the small intestine. Increased mRNA expression of hepatic Cyp3a11 and Cyp2b10 by phenobarbital was significantly suppressed in the hepatitis model mice. Hepatitis also suppressed the increased CYP3A enzymatic activity induced by phenobarbital in liver S9, consistent with the results of Cyp3a11 mRNA expression. These results suggest that the inducibility of CYP by phenobarbital may vary in patients with hepatitis, indicating that pharmacokinetic drug–drug interactions can be altered under certain pathological conditions.


  • Changes in the expression of drug-metabolising enzymes and drug transporters in mice with collagen antibody-induced arthritis

    by Chieri Fujino, Satoshi Ueshima, Toshiya Katsura

    1. We investigated the changes in the expression of drug-metabolising enzymes and drug transporters in the liver, small intestine and kidney of mice with collagen antibody-induced arthritis (CAIA) to determine whether changes in these expressions affect pharmacokinetics of drugs in patients with rheumatoid arthritis. 2. mRNA expression levels of cytochrome P450 (Cyp) 2b10, Cyp2c29 and Cyp3a11 were observed to be lower in the liver and small intestine of CAIA mice than in control mice. Compared with control mice, mRNA expression levels of multidrug resistance 1 b, peptide transporter 2 and organic anion transporter (Oat) 2 were high in the liver of CAIA mice. Changes in these expression levels were different among organs. However, elevated expression of Oat2 mRNA was not associated with an increase in protein expression and transport activity evaluated using [3H]cGMP as a substrate. 3. These results suggest that arthritis can change the expression of pharmacokinetics-related genes, but the changes may not necessarily be linked to the pharmacokinetics in patients with rheumatoid arthritis. On the other hand, we found Oat2 mRNA expression level was positively correlated with plasma interleukin-6 level, indicating that transcriptional activation of Oat2 may occur in inflammatory state.


  • Population Pharmacokinetics and Pharmacodynamics of Apixaban Linking Its Plasma Concentration to Intrinsic Activated Coagulation Factor X Activity in Japanese Patients with Atrial Fibrillation

    by Satoshi Ueshima, Daiki Hira, Chiho Tomitsuka, Miki Nomura, Yuuma Kimura, Takuya Yamane, Yohei Tabuchi, Tomoya Ozawa, Hideki Itoh, Minoru Horie, et al.

    Apixaban is used in the prevention and treatment of patients with deep vein thrombosis or pulmonary embolism, and in the prevention of stroke or systemic embolism in patients with nonvalvular atrial...


  • Open Access

    Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation

    by Satoshi Ueshima, Daiki Hira, Yuuma Kimura, Ryo Fujii, Chiho Tomitsuka, Takuya Yamane, Yohei Tabuchi, Tomoya Ozawa, Hideki Itoh, Seiko Ohno, et al.

    Aims: This study aimed to analyse the effects of genetic polymorphisms in drug transporters and metabolizing enzymes, and clinical laboratory data on the pharmacokinetic parameters of apixaban.Methods: Data were collected from 81 Japanese patients with atrial fibrillation. Pharmacogenomic data were stratified by ABCB1, ABCG2 and CYP3A5 polymorphisms. The pharmacokinetic profile of apixaban was described by a one‐compartment model with first‐order absorption. Population pharmacokinetic analysis was conducted using a nonlinear mixed effect modelling (NONMEM™) program.Results: The nonlinear relationship between oral clearance (CL/F) of apixaban and creatinine clearance (Ccr) was observed. The population mean of CL/F for a typical patient (Ccr value of 70 ml min−1) with the CYP3A5*1/*1 and ABCG2 421C/C or C/A genotypes was estimated to be 3.06 l h−1. When Ccr values were set to the typical value, the population mean of CL/F was 1.52 times higher in patients with the CYP3A5*1/*1 genotype compared with patients with the CYP3A5*1/*3 or *3/*3 genotype, while the population mean of CL/F was 1.49 times higher in patients with the ABCG2 421C/C or C/A genotype compared with patients with the ABCG2 421A/A genotype. However, no covariates affected the population mean of the apparent volume of distribution (Vd/F) of apixaban. The population mean of Vd/F was estimated to be 24.7 l.Conclusion: The present study suggests that the ABCG2 421A/A and CYP3A5*3 genotypes and renal function are intrinsic factors affecting apixaban pharmacokinetics. These findings may provide useful information for precision medicine using apixaban, to avoid the risk of adverse reactions.


  • Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation

    by Satoshi Ueshima, Daiki Hira, Ryo Fujii, Yuuma Kimura, Chiho Tomitsuka, Takuya Yamane, Yohei Tabuchi, Tomoya Ozawa, Hideki Itoh, Minoru Horie, et al.

    During anticoagulant therapy, major bleeding is one of the most severe adverse effects. This study aimed to evaluate the relationships between ABCB1, ABCG2, and CYP3A5 polymorphisms and plasma trough concentrations of apixaban, a direct inhibitor of coagulation factor X. A total of 70 plasma concentrations of apixaban from 44 Japanese patients with atrial fibrillation were analyzed. In these analyses, the plasma trough concentration/dose (C/D) ratio of apixaban was used as a pharmacokinetic index and all data were stratified according to the presence of ABCB1 (ABCB1 1236C>T, 2677G>T/A, and 3435C>T), ABCG2 (ABCG2 421C>A), and CYP3A5 (CYP3A5*3) polymorphisms. Influences of various clinical laboratory parameters (age, serum creatinine, estimated glomerular filtration rate, aspartate amino transferase, and alanine amino transferase) on the plasma trough C/D ratio of apixaban were included in analyses. Although no ABCB1 polymorphisms affected the plasma trough C/D ratio of apixaban, the plasma trough C/D ratio of apixaban was significantly higher in patients with the ABCG2 421A/A genotype than in patients with the ABCG2 421C/C genotype (P<0.01). The plasma trough C/D ratio of apixaban in patients with CYP3A5*1/*3 or *3/*3 genotypes was also significantly higher than that in patients with the CYP3A5*1/*1 genotype (P<0.05). Furthermore, the plasma trough C/D ratio of apixaban decreased with increased estimated glomerular filtration rate. These results indicate that ABCG2 421A/A and CYP3A5*3 genotypes and renal function are considered potential factors affecting trough concentrations of apixaban.


  • Open Access

    Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin‐induced lactic acidosis

    by K Toyama, A Yonezawa, S Masuda, R Osawa, M Hosokawa, S Fujimoto, N Inagaki, K Inui, T Katsura

    BACKGROUNDS AND PURPOSE: Lactic acidosis is a fatal adverse effect of metformin, but the risk factor remains unclear. Multidrug and toxin extrusion 1 (MATE1) is expressed in the luminal membrane of the kidney and liver. MATE1 was revealed to be responsible for the tubular and biliary secretion of metformin. Therefore, some MATE polymorphisms, that cause it to function abnormally, are hypothesized to induce lactic acidosis. The purpose of this study is to clarify the association between MATE dysfunction and metformin‐induced lactic acidosis.EXPERIMENTAL APPROACH: Blood lactate, pH and bicarbonate ion (HCO3‐) levels were evaluated during continuous administration of 3 mg·mL−1 metformin in drinking water using Mate1 knockout (−/−), heterozygous (+/−) and wild‐type (+/+) mice. To determine the tissue accumulation of metformin, mice were given 400 mg·kg−1 metformin orally. Furthermore, blood lactate data were obtained from diabetic patients given metformin.KEY RESULTS: Seven days after metformin administration in drinking water, significantly higher blood lactate, lower pH and HCO3‐ levels were observed in Mate1−/− mice, but not in Mate1+/− mice. The blood lactate levels were not affected in patients with the heterozygous MATE variant (MATE1‐L125F, MATE1‐G64D, MATE2‐K‐G211V). Sixty minutes after metformin administration (400 mg·kg−1, p.o.) the hepatic concentration of metformin was markedly higher in Mate1−/− mice than in Mate1+/+ mice.CONCLUSION AND IMPLICATIONS: MATE1 dysfunction caused a marked elevation in the metformin concentration in the liver and led to lactic acidosis, suggesting that the homozygous MATE1 variant could be one of the risk factors for metformin‐induced lactic acidosis.


  • Larger Dosage Required for Everolimus than Sirolimus to Maintain Same Blood Concentration in Two Pancreatic Islet Transplant Patients with Tacrolimus

    by Eriko Sato, Ikuko Yano, Masahiro Shimomura, Satohiro Masuda, Toshiya Katsura, Shin-Ichi Matsumoto, Teru Okitsu, Yasuhiro Iwanaga, Shinji Uemoto, Ken-Ichi Inui

    We attempted a switch of mammalian target of rapamycin (mTOR) inhibitors from sirolimus to everolimus, a derivative of sirolimus and now on the market in Japan, in two pancreatic islet transplant patients. Both patients were administered tacrolimus with sirolimus or everolimus. They had been administered 5 or 9 mg sirolimus once a day and had maintained a trough concentration of about 15 ng/mL as measured by high performance liquid chromatography with ultraviolet detection. After the switch from sirolimus to everolimus, they were given 10 or 12 mg/day of everolimus twice a day to maintain a trough concentration of 12-15 ng/mL as measured by a fluorescence polarization immunoassay (FPIA) method. Afterward, the blood concentrations of everolimus and sirolimus after the conversion were measured by high performance liquid chromatography with mass spectrometry and everolimus concentrations were found to be 5-10 ng/mL. These data show that a larger dosage is needed for everolimus than sirolimus to maintain the same trough blood concentration. Data obtained by the FPIA for everolimus should be carefully evaluated after switching from sirolimus to everolimus because of the cross-reactivity of the antibody with sirolimus.